Aptahem organizes an online Sepsis seminar on World Sepsis Day 13 September
Aptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company’s main candidate, is under development and intended as an emergency drug to prevent the occurrence of organ and tissue damage in patients suffering from sepsis.
Every year, approx. 40,000 people suffer from sepsis in Sweden. Totally, worldwide between 47-50 million people are affected, of which approx. 11 million die from sepsis (www.globalsepsisalliance.org).
To notice the WSD, Aptahem is arranging an online Sepsis Seminar on September 13 at 3.00-5.30 pm CET. The presentations will be in English.
|Aptahem introduction||Mikael Lindstam, CEO Aptahem|
|Sepsis; clinical manifestations, treatment and ongoing research||Mats Eriksson, Associate Professor, Section of Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, Sweden|
|Sepsis – Laboratory diagnostics
A focus on neutrophils
|Anders Larsson, Professor, Department of Clinical Chemistry and Pharmacology, Uppsala University, Sweden|
|Future diagnostics of sepsis – SepsIT®||Anna-Karin Pernestig, Associate Professor in Biosciences, University of Skövde, Sweden|
|Aptahem – ongoing research:|
|Apta-1 – a drug candidate to fight sepsis||Luiza Jedlina, PhD, CSO Aptahem|
|Apta-1 and Covid-19||Mingyao Liu, MD, Senior Scientist, Toronto General Hospital Research Institute, Canada|
|Sepsis meeting Apta-1 and Haemostasis||Magnus Grenegård, Professor, School of Medical Sciences, Örebro University, Sweden|
|Closure||Mikael Lindstam, CEO Aptahem|
The seminar is free of charge and does not require any registration. Link to the event will be available at aptahem.com.
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.
* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.